Compare Abbott Laboratories (ABT) vs Diageo plc (DEO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abbott Laboratories vs Diageo plc — how do they compare? Abbott Laboratories trades at $95.21 (market cap $166.94B), while Diageo plc trades at $81.06 (market cap $45.92B). The key difference: Abbott Laboratories is far larger — about 3.6× Diageo plc's market cap, and Diageo plc pays the higher dividend (4.01%). Which is the better fit depends on your goals.
| ABT | DEO | |
|---|---|---|
Market Cap | $166.94B | $45.92B |
Sector | Health | Technology |
52-Week High | $136.62 | $115.33 |
52-Week Low | $82.57 | $72.47 |
Enterprise Value | $193.69B | $66.74B |
Dividend Yield | 2.63% | 4.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Abbott Laboratories (ABT) trades at $95.63, up 0.25% on the day, with a bullish technical signal from moving averages and strong analyst support. The stock shows solid fundamentals with a P/E of 26.79 and net income margin of 13.91%, though recent earnings have been mixed. Recent news highlights regulatory approvals for new medical devices, supporting growth prospects.
The outlook remains positive with a consensus price target of $122.55, implying significant upside. Key risks include competitive pressures and macroeconomic headwinds, but strong institutional backing and consistent dividend payments provide stability for long-term investors.
Diageo (DEO) trades at $81.67, down 0.6% on the day, with a neutral technical signal and mixed earnings history. The stock shows strong profitability with a 12.19% net margin and 22.29% ROE, but faces headwinds in the US spirits market. Recent news highlights CEO Dave Lewis's upcoming strategy update amid concerns over US demand and promotional pressures.
The outlook is cautious with analyst consensus leaning buy (48.65%) but significant hold ratings (43.24%). Key risks include US market weakness and shifting consumer trends, while opportunities lie in premiumization and innovation. The stock's valuation at a P/E of 18.87 appears reasonable if recovery initiatives gain traction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Abbott Laboratories
Abbott manufactures and markets medical devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, molecular diagnostic platforms, and immunoassays and point-of-care diagnostic equipment. Abbott derives approximately 60% of sales outside the United States.
Read more on ABT →About Diageo plc
Diageo is a global leader in beverage alcohol with an outstanding collection of brands including Johnnie Walker, Smirnoff, and Guinness. It operates a vast portfolio of spirits and beers across more than 180 countries.
Read more on DEO →
